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Background
In colorectal cancer (CRC), the third most common cause
of cancer and cancer death for both men and women in
the USA, the steps necessary for carcinogenesis have been
well defined. However, the genetic changes necessary for
tumor evolution to metastasis are not as well elucidated.
Therefore, we searched for the presence of mutations
in key cancer genes in primary and metastatic colorectal
cancer to determine whether primary or metastatic tissue
is ideal for biomarker analysis and to identify putative
biomarkers.
Materials and methods
Fifty patient-matched primary tumor, metastatic tumor
and normal samples from CRC patients were sequenced
using a panel of 230 genes that are actionable, have been
shown to be mutated in human tumors, and/or are part
of commonly dysregulated pathways. This assay, coined
IMPACT (Integrated Mutation Profiling of Actionable
Cancer Targets), provided sequence data to a median
depth of coverage of 644X, allowing for identification of
low-frequency genetic events. Mutations, insertion/dele-
tions (indels) and copy number events were analyzed
comparing both primary and metastatic samples with the
corresponding patient normal.
Results
The majority of genetic events were identical between pri-
mary and metastatic tumors; most frequently mutated
were the genes commonly associated with CRC, such as
APC, TP53, KRAS and PIK3CA. A number of mutations
were found only in the primary samples, suggesting that
these events were not important for tumor progression.
Most interesting were the identification of genetic events
specific to the metastatic sample: the majority of these
alterations were members of two important proliferative
pathways, further lending credence that they might play
an important role in metastatic progression. Importantly,
one of these pathways can be targeted by a number of
FDA-approved therapies.
Conclusions
While the majority of primary and metastatic tumors pre-
sent with the same genetic events in key cancer genes,
additional events in critical pathways were specific to the
corresponding metastatic tumors. Further analysis is in
process to determine whether these differences are caused
by sampling biases within the primary tumor that could be
rectified in clinical analysis. The identification of these
genetic variations between primary and metastatic tumors
could have significant impact on biomarker analysis as
well treatment decisions for CRC patients.
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